These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 11425308)

  • 1. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.
    Volles MJ; Lee SJ; Rochet JC; Shtilerman MD; Ding TT; Kessler JC; Lansbury PT
    Biochemistry; 2001 Jul; 40(26):7812-9. PubMed ID: 11425308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
    Park JY; Lansbury PT
    Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
    Conway KA; Harper JD; Lansbury PT
    Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes.
    Ding TT; Lee SJ; Rochet JC; Lansbury PT
    Biochemistry; 2002 Aug; 41(32):10209-17. PubMed ID: 12162735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.
    Volles MJ; Lansbury PT
    Biochemistry; 2002 Apr; 41(14):4595-602. PubMed ID: 11926821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?
    Shtilerman MD; Ding TT; Lansbury PT
    Biochemistry; 2002 Mar; 41(12):3855-60. PubMed ID: 11900526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.
    Rochet JC; Outeiro TF; Conway KA; Ding TT; Volles MJ; Lashuel HA; Bieganski RM; Lindquist SL; Lansbury PT
    J Mol Neurosci; 2004; 23(1-2):23-34. PubMed ID: 15126689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
    Lashuel HA; Petre BM; Wall J; Simon M; Nowak RJ; Walz T; Lansbury PT
    J Mol Biol; 2002 Oct; 322(5):1089-102. PubMed ID: 12367530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
    Conway KA; Lee SJ; Rochet JC; Ding TT; Williamson RE; Lansbury PT
    Proc Natl Acad Sci U S A; 2000 Jan; 97(2):571-6. PubMed ID: 10639120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation.
    Zhu M; Li J; Fink AL
    J Biol Chem; 2003 Oct; 278(41):40186-97. PubMed ID: 12885775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.
    Rochet JC; Conway KA; Lansbury PT
    Biochemistry; 2000 Sep; 39(35):10619-26. PubMed ID: 10978144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
    Volles MJ; Lansbury PT
    Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein.
    Bussell R; Eliezer D
    Biochemistry; 2004 Apr; 43(16):4810-8. PubMed ID: 15096050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.
    Jensen PH; Nielsen MS; Jakes R; Dotti CG; Goedert M
    J Biol Chem; 1998 Oct; 273(41):26292-4. PubMed ID: 9756856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
    Conway KA; Rochet JC; Bieganski RM; Lansbury PT
    Science; 2001 Nov; 294(5545):1346-9. PubMed ID: 11701929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Conway KA; Harper JD; Lansbury PT
    Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.
    Emadi S; Liu R; Yuan B; Schulz P; McAllister C; Lyubchenko Y; Messer A; Sierks MR
    Biochemistry; 2004 Mar; 43(10):2871-8. PubMed ID: 15005622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease-associated alpha-synuclein is a calmodulin substrate.
    Martinez J; Moeller I; Erdjument-Bromage H; Tempst P; Lauring B
    J Biol Chem; 2003 May; 278(19):17379-87. PubMed ID: 12610000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of heparan sulfate proteoglycans in Lewy bodies and Lewy neurites in Parkinson's disease brains.
    van Horssen J; de Vos RA; Steur EN; David G; Wesseling P; de Waal RM; Verbeek MM
    J Alzheimers Dis; 2004 Oct; 6(5):469-74. PubMed ID: 15505367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease.
    Liani E; Eyal A; Avraham E; Shemer R; Szargel R; Berg D; Bornemann A; Riess O; Ross CA; Rott R; Engelender S
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5500-5. PubMed ID: 15064394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.